200 related articles for article (PubMed ID: 24066060)
1. Unique anti-glioblastoma activities of hypericin are at the crossroad of biochemical and epigenetic events and culminate in tumor cell differentiation.
Dror N; Mandel M; Lavie G
PLoS One; 2013; 8(9):e73625. PubMed ID: 24066060
[TBL] [Abstract][Full Text] [Related]
2. Transcriptome analysis evinces anti-neoplastic mechanisms of hypericin: A study on U87 glioblastoma cell line.
Ghiasvand S; Javidi MA; Mohammadian A; Mousavi SA; Shahriari F; Alavian F
Life Sci; 2021 Feb; 266():118874. PubMed ID: 33358904
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
[TBL] [Abstract][Full Text] [Related]
4. Mitochondria-targeting nano therapy altering IDH2-mediated EZH2/EZH1 interaction as precise epigenetic regulation in glioblastoma.
Kaundal B; Karmakar S; Roy Choudhury S
Biomater Sci; 2022 Sep; 10(18):5301-5317. PubMed ID: 35917200
[TBL] [Abstract][Full Text] [Related]
5. Degradation of HIF-1alpha under hypoxia combined with induction of Hsp90 polyubiquitination in cancer cells by hypericin: a unique cancer therapy.
Barliya T; Mandel M; Livnat T; Weinberger D; Lavie G
PLoS One; 2011; 6(9):e22849. PubMed ID: 21949677
[TBL] [Abstract][Full Text] [Related]
6. Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme.
Li Q; Dong C; Cui J; Wang Y; Hong X
J Exp Clin Cancer Res; 2018 Oct; 37(1):265. PubMed ID: 30376874
[TBL] [Abstract][Full Text] [Related]
7. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
8. Quercetin modifies 5'CpG promoter methylation and reactivates various tumor suppressor genes by modulating epigenetic marks in human cervical cancer cells.
Kedhari Sundaram M; Hussain A; Haque S; Raina R; Afroze N
J Cell Biochem; 2019 Oct; 120(10):18357-18369. PubMed ID: 31172592
[TBL] [Abstract][Full Text] [Related]
9. Subcellular colocalization of hypericin with respect to endoplasmic reticulum and Golgi apparatus in glioblastoma cells.
Ritz R; Roser F; Radomski N; Strauss WS; Tatagiba M; Gharabaghi A
Anticancer Res; 2008; 28(4B):2033-8. PubMed ID: 18751371
[TBL] [Abstract][Full Text] [Related]
10. Polycomb complex mediated epigenetic reprogramming alters TGF-β signaling via a novel EZH2/miR-490/TGIF2 axis thereby inducing migration and EMT potential in glioblastomas.
Vinchure OS; Sharma V; Tabasum S; Ghosh S; Singh RP; Sarkar C; Kulshreshtha R
Int J Cancer; 2019 Sep; 145(5):1254-1269. PubMed ID: 31008529
[TBL] [Abstract][Full Text] [Related]
11. Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation.
Chistiakov DA; Orekhov AN; Bobryshev YV
Int J Cardiol; 2017 Jan; 227():66-82. PubMed ID: 27852009
[TBL] [Abstract][Full Text] [Related]
12. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma.
Natsume A; Ito M; Katsushima K; Ohka F; Hatanaka A; Shinjo K; Sato S; Takahashi S; Ishikawa Y; Takeuchi I; Shimogawa H; Uesugi M; Okano H; Kim SU; Wakabayashi T; Issa JP; Sekido Y; Kondo Y
Cancer Res; 2013 Jul; 73(14):4559-70. PubMed ID: 23720055
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
Ramaiah MJ; Tangutur AD; Manyam RR
Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
Christofides A; Karantanos T; Bardhan K; Boussiotis VA
Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
16. DNA methyltransferase inhibitor RG108 and histone deacetylase inhibitors cooperate to enhance NB4 cell differentiation and E-cadherin re-expression by chromatin remodelling.
Savickiene J; Treigyte G; Jazdauskaite A; Borutinskaite VV; Navakauskiene R
Cell Biol Int; 2012 Nov; 36(11):1067-78. PubMed ID: 22845560
[TBL] [Abstract][Full Text] [Related]
17. HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components.
Lopez G; Song Y; Lam R; Ruder D; Creighton CJ; Bid HK; Bill KL; Bolshakov S; Zhang X; Lev D; Pollock RE
Mol Cancer Res; 2016 Jan; 14(1):35-43. PubMed ID: 26396249
[TBL] [Abstract][Full Text] [Related]
18. A Succinate Ether Derivative of Tocotrienol Enhances Dickkopf-1 Gene Expression through Epigenetic Alterations in Malignant Mesothelioma Cells.
Sato A; Ueno H; Fusegi M; Kaneko S; Kohno K; Virgona N; Ando A; Sekine Y; Yano T
Pharmacology; 2018; 102(1-2):26-36. PubMed ID: 29763912
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase (HDAC) activity is critical for embryonic kidney gene expression, growth, and differentiation.
Chen S; Bellew C; Yao X; Stefkova J; Dipp S; Saifudeen Z; Bachvarov D; El-Dahr SS
J Biol Chem; 2011 Sep; 286(37):32775-89. PubMed ID: 21778236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
